389
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
DEVELOPMENT OF NEW PHARMACEUTICAL PRODUCTS BASED ON THE
PLANT OBJECT
ELAEAGNUS ANGUSTIFOLIA L.
Rakhymbaev Nurgali Amanbayuly
School of Pharmacy, Kazakh National Medical University named after
S.D. Asfendiyarov, Almaty, Kazakhstan,
E-mail: nr_farma@mail.ru, Tel.: +7 778 656 78 26
https://doi.org/10.5281/zenodo.17339416
Relevance:
The increase in chronic diseases, multi-organ pathology, and complications from
long-term use of synthetic drugs necessitates the search for alternative sources of medicines with
minimal side effects. In this context, interest in herbal medicines with comprehensive effects and
good tolerability is growing.
Elaeagnus angustifolia
(narrow-leaved oleaster) has traditionally been
used in folk medicine as an analgesic and anti-inflammatory agent. Modern studies confirm the
presence of bioactive compounds (BACs) in this plant, which can serve as the basis for the
development of effective and safe pharmaceutical products, exhibiting antioxidant, analgesic, and
antibacterial activities.
Objective.
To review current data on the chemical composition and pharmacological properties
of
Elaeagnus angustifolia
as a basis for the development of new pharmaceutical products.
Materials and Methods.
Literature analysis was carried out using PubMed, Scopus, and
eLibrary databases for the period 2015–2024. Publications on the phytochemical composition,
mechanisms of action, and applications of plant extracts were considered.
Results.
Studies have shown that extracts from the fruits, leaves, and flowers of
Elaeagnus
angustifolia
contain flavonoids such as quercetin and isorhamnetin, as well as polyphenolic
compounds, tannins, amino acids, organic acids, vitamins (C, E), and trace elements. These
components provide pronounced antioxidant, analgesic, anti-inflammatory, and antibacterial
properties. For example, fruit extracts demonstrated the ability to inhibit DPPH and ABTS radicals
as well as superoxide anions, confirming their antioxidant activity.
Clinical studies confirm the efficacy of
Elaeagnus angustifolia
-based preparations in the
treatment of inflammatory joint diseases and pain syndromes. One randomized controlled trial
showed that
Elaeagnus angustifolia
extract in combination with
Boswellia thurifera
exhibited anti-
inflammatory and analgesic effects comparable to ibuprofen in patients with knee osteoarthritis.
Additionally,
Elaeagnus angustifolia
extracts demonstrated hypoglycemic activity. Animal
studies showed that polysaccharides from the plant's fruits reduced blood glucose levels in mice with
type 2 diabetes.
Conclusions.
Elaeagnus angustifolia
is a promising object for pharmaceutical development
due to its high content of BACs and multifaceted pharmacological activity. The creation of new herbal
medicines requires further research on raw material standardization, optimization of extraction
methods, study of mechanisms of action, and preclinical and clinical trials. An important direction is
the development of innovative dosage forms (nano-structured extracts, phytogels, dietary
supplements), which will enhance the bioavailability and effectiveness of active compounds.
